Physiological roles of NOX/NADPH oxidase, the superoxide-generating enzyme by Katsuyama, Masato et al.
Serial Review
 J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 9–22 doi: 10.3164/jcbn.11 06SR
©2012 JCBN
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn11-06SR 10.3164/jcbn.11-06SR Review Physiological Relevance of Antioxid/Redox Genes; 
Learning from Genetically Modified Animals
Guest Editor: Junichi Fujii
Physiological roles of NOX/NADPH oxidase, 
the superoxide generating enzyme
Masato Katsuyama,1,* Kuniharu Matsuno2 and Chihiro Yabe Nishimura2
1Radioisotope Center and 2Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto 602 8566, Japan
*To whom correspondence should be addressed.    
E mail: mkatsuya@koto.kpu m.ac.jp
?? (Received 6 January, 2011; Accepted 17 February, 2011; Published online 17 June, 2011)
Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. NADPH oxidase is a superoxide (O2￿−) generating enzyme first
identified in phagocytes, essential for their bactericidal activities.
Later, in non phagocytes, production of O2￿− was also demonstrated
in an NADPH dependent manner. In the last decade, several non 
phagocyte type NADPH oxidases have been identified. The catalytic
subunit of these oxidases, NOX, constitutes the NOX family. There
are five homologs in the family, NOX1 to NOX5, and two related
enzymes, DUOX1 and DUOX2. Transgenic or gene disrupted mice
of the NOX family have also been established. NOX/DUOX proteins
possess distinct features in the dependency on other components
for their enzymatic activities, tissue distributions, and physio 
logical functions. This review summarized the characteristics of
the NOX family proteins, especially focused on their functions
clarified through studies using gene modified mice.
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Introduction Reactive oxygen species (ROS) including hydrogen peroxide
(H2O2), hydroxyl radical, singlet oxygen, peroxynitrite, and
superoxide (O2￿−) have been documented to possess both beneficial
and detrimental properties at the same time. On one hand, ROS
exert bactericidal activities by oxidizing infected microorganisms.
On the other hand, ROS elicit lipid peroxidation and inactivate
nitric oxide (NO) that dilates blood vessels.
Major sources of O2￿− generated in the body are NADPH oxi-
dases. These oxidases produce O2￿− from oxygen using NADPH
as an electron donor. Studies on NADPH oxidases have been
energetically performed mainly in phagocytes, neutrophils. This is
because mutations in the gene encoding the phagocyte NADPH
oxidase were found in patients with chronic granulomatous disease
(CGD).(1) In CGD patients, generation of O2￿− and bactericidal
activity are attenuated in phagocytes due to the defects in NOX2/
NADPH oxidase. This leads to the formation of granulomas in the
lung, liver, lymph nodes, and gastrointestinal tracts. The phagocyte
NADPH oxidase is composed of two membrane subunits gp91phox
(cytochrome b558 heavy chain; later designated as NOX2) and
p22phox, three cytosolic subunits p67phox, p47phox, and p40phox,
and a small GTP-binding protein Rac. NOX2 is the catalytic
subunit of this enzyme complex. Bacterial infection induces
association and translocation of the cytosolic components to the
phagosome membrane, which elicits activation of the enzyme.
In recent years it has been reported that O2￿− is produced in
non-phagocytes such as vascular smooth muscle cells (VSMC)
and gastrointestinal epithelial cells in an NADPH-dependent
manner. Since NOX2 is not expressed in these cells, the presence
of non-phagocyte-type NOX homologs has been assumed. A
novel homolog, highly expressed in colon epithelial cells (CEC),
was first reported by Suh et al.(2) in 1999 and by Banfi et al.(3)
in 2000. This homolog was designated as NOX1. To date, five
NOX isoforms (NOX1, NOX2, NOX3, NOX4, and NOX5) and
two related enzymes, DUOX1 and DUOX2, were identified.
NOX enzymes have six transmembrane domains at the N-
terminal half. In the third and fifth transmembrane domains,
four heme-binding histidines were conserved. In the C-terminal
cytosolic region, they have an FAD-binding domain and an
NADPH-binding domain. As for NOX5, it has additional EF-hands,
the Ca2+-binding domains, at the N-terminus. In addition to EF-
hands, DUOX enzymes have a membrane-spanning region and a
peroxidase-like domain at the N-terminus (Fig. 1).
NOX2
Activation of NOX2/NADPH oxidase by cytosolic compo 
nents. As mentioned above, NOX2 was first designated as
gp91phox (cytochrome b558 heavy chain), the catalytic subunit
of the phagocyte NADPH oxidase. The NOX2 gene was identified
as a responsible gene for CGD.(1) NOX2/NADPH oxidase is
composed of NOX2, p22phox, p67phox, p47phox, p40phox, and
a small GTP-binding protein Rac (Fig. 1). Activation mechanisms
of NOX2/NADPH oxidase have been studied by many groups and
documented.(4,5) NOX2 and p22phox are located at the plasma
membrane and stabilize each other. Through its C-terminal Src
homology 3 (SH3) domain, p67phox is associated with the C-
terminal proline-rich region (PRR) of p47phox. The cytosolic
subunit p47phox has two SH3 domains necessary for its associa-
tion with the C-terminal PRR of p22phox. In the resting state, the
SH3 domains of p47phox bind intramolecularly to the autoinhibi-
tory region (AIR) in the C-terminal half, interrupting binding to
p22phox. The N-terminal phagocyte oxidase (PX) domain of
p47phox is necessary for binding to membrane phosphoinositides.
Another cytoplasmic component p40phox is associated with
p67phox via mutual Phox/Bem1p (PB1) domains. Phagocytosis
of bacteria or stimulation with phorbol ester (TPA) induces phos-
phorylation and conformational change in p47phox, enabling its
binding to p22phox. Rac is associated with GDP nucleotides
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Table 1. Characteristics of NOX isoforms
Isoform Human gene locus Coupling components Major distribution sites Related disorders
NOX1 Xq22 p22phox  colon epithelium hypertension, aortic dissection (aneurysm), 
neointima formation
NOXA1/p67phox VSMC inflammatory pain, cerebral ischemia, 
neuroinflammation
NOXO1/p47phox hyperoxia induced acute lung injury
Rac colorectal cancer
NOX2 Xp21.1 p22phox phagocyte cardiac hypertrophy, fibrosis, heart failure
p67phox myocardial infarction, neovascularization 
(ischemic cardiovascular diseases)
p47phox Alzheimer’s disease, Parkinson’s disease, 
ischemic stroke
p40phox neuropathic pain (peripheral nerve injury)
Rac glutamate release (schizophrenia)
liver fibrosis, Liver ischemia and reperfusion injury
amyotrophic lateral sclerosis (ALS)
NOX3 6q25.3 p22phox inner ear development of the otoconia
NOXA1/p67phox hearing loss
NOXO1/p47phox insulin resistance (diabetes)
Rac
NOX4 11q14.2 q21 p22phox kidney (many other organs) mitochondrial dysfunction 
(cardiac hypertrophy, interstitial fibrosis)
sympathetic nerve activity 
(heart failure, myocardial infarction)
pulmonary fibrosis, pulmonary hypertension
diabetic nephropathy, renal cancer
NOX5 15q22.31 spleen, testis, lymph node Barrett’s esophagus, prostate cancer
DUOX1 15q21 DUOXA1 (maturation factor) thyroid host defense
DUOX2 15q15.3 DUOXA2 (maturation factor) thyroid hypothyroidism, host defense
Fig. 1. Schematic diagrams of NOX/NADPH oxidases. EF, EF hands. PRX, peroxidase like domain. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 11
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dissociation inhibitor for Rho (RhoGDI) in the cytosol. With
stimulation, Rac translocates to the membrane independently of
p47phox and p67phox. GTP-bound Rac interacts with the N-
terminal region of p67phox containing four tetratricopeptide repeat
(TPR) motifs. Thus, translocation of cytosolic components to the
phagosome membrane and association with the membrane subunits
lead to the activation of the enzyme.
Transcriptional regulation of NOX2. In addition to the
regulation of the enzymatic activity by cytosolic components, the
expression level of NOX2 is regulated at the level of transcription.
Point mutations at −57, −55, −53, and −52 of the NOX2 gene have
been detected in patients with CGD.(6,7) The transcription of NOX2
is restricted to myeloid cells differentiated beyond the promyelo-
cyte stage. Interferon (IFN)-γ and lipopolysaccharide (LPS) were
shown to increase the expression level of NOX2 in human mono-
cyte-derived macrophages and neutrophils.(8) TPA or retinoic acid/
dimethylformamide (DMF) was also reported to induce NOX2
expression in myeloid cells.(9) A number of DNA-binding proteins
were shown to interact with the NOX2 promoter region, including
BID (binding increased during differentiation), IFN regulatory
factor (IRF)-1, IRF-2, the CCAAT box binding protein CP1, and
the transcriptional repressor CDP (CCAAT displacement protein)
(Fig. 2).(9–13) Voo and Skalnik reported that Elf-1 and PU.1, both of
which are Ets family transcription factors highly expressed in
myeloid cells, bound to the region containing −57/−52 of the
NOX2 gene (Fig. 2). Point mutation at –57 or –55 found in CGD
patients was shown to reduce the binding affinity and activity of
Elf-1 and PU.1.(14) Protein kinase C (PKC)-dependent phosphory-
lation of PU.1 was reported to be involved in IFN-γ-induced
expression of NOX2 in human monocytes.(15) Bei et al.(16) reported
that the transcription of NOX2 during myeloid differentiation
was activated by HoxA9 but repressed by HoxA10, both of which
are homeodomain transcription factors (Fig. 2). They also found
HoxA10-dependent transcriptional repression of p67phox.(17)
Tyrosine phosphorylation by Janus tyrosine kinase 2 (JAK2),
which is activated by stimulation with IFN-γ, was shown to
decrease DNA-binding activity of HoxA10 that represses NOX2
transcription.(18) On the other hand, activation of SHP-2 protein-
tyrosine phosphatase was shown to increase HoxA10-induced
transcriptional repression of NOX2 and p67phox.(19) Yang et al.(20)
reported that GATA-1 was an activator, while GATA-2 was a rela-
tive competitive inhibitor of GATA-1 in the eosinophil-specific
expression of NOX2 (Fig. 2). NF-κB-dependent transcription of
NOX2 was also reported, suggesting the presence of a positive
feedback loop in which NF-κB activation by oxidative stress leads
to further oxidative burst via NOX2/NADPH oxidase.(21)
Physiological roles of NOX2/NADPH oxidase. Numerous
reports using NOX2-deficient mice have been published as an
animal model of CGD.(22–24) In this review, only recent findings on
the roles NOX2/NADPH oxidase are summarized. Many of the
previous studies focused on the function of NOX2 in vascular
tissues. Recent findings further showed that NOX2 expressed in
bone marrow (BM) and endothelial progenitor cells (EPC) takes
part in neovascularization induced by hindlimb ischemia.(25) After
hindlimb ischemia induced by ligation of femoral artery, the
expression of NOX2 and ROS production were significantly
increased in BM-mononuclear cells (BMC). Increased circulation
of EPC-like cells was observed in wild type mice, but blunted in
NOX2-deficient mice. Impaired neovascularization following
hindlimb ischemia in NOX2-deficient mice was rescued by trans-
plantation of BM from wild type mice. Intravenous infusion of
BMC derived from NOX2-deficient mice to wild type mice revealed
that the neovascularization and homing capacity are impaired in
BMC derived from NOX2-deficient mice. Migration and invasion
capacity as well as polarization of actins induced by stromal
derived factor were significantly suppressed in BM stem/progenitor
cells of NOX2-deficient mice. Accordingly, these findings suggest
that NOX2-derived ROS regulate EPC mobilization from BM as
well as their homing to promote neovascularization following
ischemic cardiovascular injuries.
In the prefrontal cortex, a novel role of NOX2 in glutamate
release was reported.(26) When the locomotor activity was mea-
sured by the frequency of crossings, rearings, groomings, and
sniffings in mice administered with ketamine, marked increases in
these parameters were observed in wild type mice with the eleva-
tion of the oxidative stress maker, 8-OHdG, and c-fos mRNA. In
contrast, these behavioral alterations like schizophrenia were not
observed in NOX2-deficient mice treated with ketamine. Micro-
dialysis in freely moving animals revealed that the ketamine-
induced increase in the extracellular concentration of glutamate
and dopamine in the brain was abolished in NOX2-deficient mice.
However,  NOX2-deficiency did not affect the release of these
neurotransmitters induced by amphetamine. After repeated injec-
tions of ketamine, a reduced expression of the subunit 2A of the
NMDA receptor was demonstrated in wild type mice but not in
NOX2-deficient mice. These findings suggest that NOX2 is
Fig. 2. Transcription factors involved in the expression of NOX2. Ovals indicate binding sites for transcription factors on the NOX2 gene. Transcrip 
tion factors were expressed as open boxes. Transcriptional repressors were expressed as shaded squares.doi: 10.3164/jcbn.11 06SR
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involved in the development of psychotic symptoms induced by
ketamine by elevating glutamate levels and down-regulating the
NMDA receptor subunit.(26)
In the spinal cord microglia, NOX2-derived ROS were docu-
mented to take part in nerve injury-induced neuropathic pain.(27)
Following spinal nerve transection (SNT), increased levels of
ROS and NOX2 mRNA were demonstrated in the spinal cord
microglia. Mechanical allodynia and thermal hyperalgesia induced
by SNT were significantly attenuated in NOX2-deficient mice.
SNT induced activation of microglia and subsequent expression of
pro-inflammatory cytokines in the spinal cord of wild type mice.
These responses were significantly suppressed in NOX2-deficient
mice. Furthermore, intrathecal administration of an antioxidant to
wild type mice reproduced similar effects observed in NOX2-
deficient mice. NOX2 in the spinal cord microglia may therefore
play a significant role in the development of neuropathic pain,
possibly by regulating proinflammatory cytokines.
In the liver, a crucial role of NOX2 in stellate cell activation and
liver fibrosis has been demonstrated.(28) In patients with hepatitis C
virus or primary biliary cirrhosis, NOX2 was expressed in α-
SMA-positive hepatic stellate cells (HSC). In bile duct ligation
(BDL)-induced liver fibrosis, increased expression of NOX2 was
in fact demonstrated in HSC isolated from mice. Treatment with
apoptotic bodies (AB) also induced NOX2 expression in isolated
HSC, indicating that the expression of NOX2 was induced
following phagocytosis. In primary cultured HSC, an anti-NOX2
small interfering RNA (siRNA) suppressed production of ROS
and induction of collagen synthesis following phagocytosis of
AB. Interestingly, phagocytotic activity was significantly decreased
in HSC isolated from NOX2-deficient mice. Phagocytosis of
apoptotic hepatocytes induced by injection of lentiviral-green
fluorescence protein with the hepatocyte-specific α1 antitrypsin
promoter and adeno-tumor necrosis factor-related apoptosis-
inducing ligand (ad-TRAIL), activated HSC and increased profi-
brogenic genes in wild type mice. In contrast, these responses
were significantly attenuated in NOX2-deficient mice. The fact
that  NOX2-deficiency significantly suppressed liver fibrosis in
BDL model suggests that NOX2 may play a central role in liver
fibrogenesis possibly by mediating activation of HSC following
phagocytosis of hepatocytes.(28)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease that can be caused by dominant mutations in superoxide
dismutase-1 (SOD1). Oxidative stress is thought to be an important
component of disease progression in ALS. Marden et al.(29) reported
that NOX2-derived ROS was an exacerbating factor of ALS. They
bred  NOX2-deficient mice crossed with hemizygous SOD1G93A
transgenic mice, a mouse model of ALS, and evaluated the
development of motor neuron disorders. Deficiency of NOX2
significantly delayed the death of hemizygous SOD1G93A ALS
mice. Production of O2￿− in the spinal cord, which was signifi-
cantly increased in SOD1G93A ALS mice, was almost completely
abolished in NOX2-deficient mice. In addition, the death of motor
neurons in the lumbar region of the spinal cord and the expression
level of the activated microglial marker, CD11b, were signifi-
cantly reduced in NOX2-deficient mice. In SOD1G93A ALS mice,
a decline in rotarod performance and stride length was observed
due to hindlimb muscle atrophy. In contrast, these symptoms
were alleviated in NOX2-deficient mice. These findings suggest
that targeted inhibition of NOX2 using pharmacologic-based
approaches may provide substantial benefits for ALS patients.
NOX1
Identification of NOX1 and its coupling components.
NOX1 was originally isolated from colon epithelial cells (CEC).(2,3)
It is also expressed in vascular smooth muscle cells (VSMC) and
other cell lineages. Its expression is induced by vasoactive factors
such as angiotensin II (Ang II) and platelet-derived growth factor
(PDGF) that elicit proliferation and hypertrophy of VSMC.(2,30)
NOX1 is also expressed in macrophages, where it was suggested
to be involved in foam cell formation.(31) In mast cells, NOX1 was
reported to take part in interleukin (IL)-1β-induced IL-8 secre-
tion(32) and in antigen-induced production of Th2 cytokines.(33)
Like NOX2, NOX1 requires other components for its enzyme
activity. In addition to the membrane subunit p22phox, p67phox,
p47phox, and Rac1 could compose NOX1/NADPH oxidase.(34,35)
Later, the p67phox homolog NOXA1 (NOX activator 1) and the
p47phox homolog NOXO1 (NOX organizer 1) were identified.
Unlike p67phox and p47phox, NOXA1 and NOXO1 were
constitutively associated with NOX1 and p22phox, respectively
(Fig. 1).(36–38) Subcellular localization of NOX1 has been docu-
mented in caveola and in early endosomes.(39,40)
Transcriptional regulation of NOX1 in colon epithelial
cells. The expression level of NOX1 is very high in the colon
compared to other organs.(2,3) The human NOX1 gene is located on
Xq22, and the mRNA is encoded by 13 exons. The initiation
codon exists in the first exon. Several groups reported the mecha-
nisms of transcriptional regulation of NOX1 in the colon. Brewer
et al.(41) reported that a GATA binding site at –135/–130 to be
essential for the basal transcriptional activity using a human
CEC line Caco-2. Valente et al.(42) reported that the four regions at
–201/–181, –177/–157, –149/–124, and –107/–88, to which
GATA-4/5/6 could bind, are essential for the basal transcriptional
activity in Caco-2 cells, and that Cdx1/2 and HNF-1α could bind
to –177/–157 and –149/–124, respectively (Fig. 3). The expres-
sion pattern of NOX1, which is highly expressed in the lower
part of large intestine, coincides with the patterns of GATA-6,
HNF-1α, and Cdx1. These transcription factors may therefore
contribute to the expression of NOX1 in the colon. Involvement of
GATA-6 in the expression of NOX1 in Caco-2 cells was also
reported, in that up-regulation of NOX1 by oncogenic Ras was
mediated by MEK-ERK-dependent phosphorylation of GATA-6.(43)
On the other hand, Kuwano et al.(44) found that NOX1 is induced
in the human CEC line T84 stimulated with IFN-γ. The γ-activated
sequence (GAS) at –3818/–3810 was essential for this induction,
and phosphorylated STAT1 could bind to this sequence upon
stimulation with IFN-γ (Fig. 3). They also reported the mechanism
of expressional regulation of NOXO1 in colon epithelial cells.
While IL-1β, flagellin, IFN-γ, and tumor necrosis factor (TNF)-α
similarly induced NOX1 expression in T84 cells, only TNF-α
fully induced NOXO1 expression. They identified three putative
binding sites for Sp1, and an AP-1 binding site as crucial elements
for the TNF-α-dependent expression of NOXO1 in the colon.(45)
Recently, NOX1/NADPH oxidase in the colon was reported to
play a key role in the balance between goblet and absorptive cell
types by regulating cell proliferation and post-mitotic differentia-
tion.(46)
Identification of novel NOX1 transcripts induced with
phenotype modulation of VSMC. While the expression level
of NOX1 in VSMC is increased by stimulation with Ang II,
PDGF, prostaglandin (PG) F2α, aldosterone/high salt, serum, or
TPA, the level is extremely low compared to that in CEC.(30,47,48)
It was therefore assumed that the expression mechanism of the
NOX1 gene is different between VSMC and CEC. When we
analyzed the 5'-end of the NOX1 mRNA, cDNAs with longer 5'-
ends were identified by 5'-RACE in a mouse VSMC line,
P53LMACO1.(49) Sequence analyses of cDNA obtained from
mouse cecum revealed that the first exon of the cecum cDNA
contained the start codon similar to the human NOX1 mRNA. On
the other hand, two novel cDNAs with additional exons at the 5'-
end were isolated from P53LMACO1 cells. We named the exon
containing the start codon as exon 1a, and additional 5'-exons as
exon 1b to 1f. Consequently, three types of mRNAs are generated
from these 5'-exons, a-type, c-type, and f-type, respectively. The
c-type and f-type contained exon 1b, and ATG in this exon was
used as the start codon, making the N terminus 28-residues longer J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 13
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than that of the a-type. The a-type was expressed not only in the
cecum but also in the intact mouse aorta. On the other hand, the
c-type was not expressed in the intact aorta, but its expression was
induced by wire injury, Ang II administration, or by culturing
aortic VSMC in the medium containing serum. As the expression
pattern of the c-type coincided with the pattern of markers
indicating phenotypic modulation of VSMC, the expression of the
c-type NOX1 might be related to dedifferentiation of VSMC.(49)
Although a sequence homologous to the rodent exon 1c was found
in the human gene, it did not seem to encode an exon. Indeed,
the c-type-like cDNA has not been isolated from human VSMC
(Katsuyama et al., unpublished data). The transcriptional regula-
tion of the NOX1 gene in VSMC therefore seems to be species-
specific.
Signaling pathways involved in induction of NOX1 in
VSMC. PGF2α, one of the primary prostanoids generated in the
vascular tissue, was known to cause hypertrophy of VSMC. We
found that this is mediated by O2￿− generated by NOX1.(47) We next
examined signaling pathways involved in the up-regulation of
NOX1.
Diphenyleneiodonium (DPI), an inhibitor of flavoproteins
including NADPH oxidase itself, almost completely suppressed
PGF2α- or PDGF-induced up-regulation of NOX1 mRNA in a rat
VSMC line, A7r5.(50) Exploration into the site of action for DPI
using various inhibitors suggested the involvement of mito-
chondrial oxidative phosphorylation. In a luciferase reporter assay,
activation of the cAMP response element (CRE)-dependent gene
transcription by PGF2α was attenuated by oligomycin, an inhibitor
of mitochondrial FoF1-ATPase. Oligomycin and other mitochon-
drial inhibitors also suppressed PGF2α-induced phosphorylation of
activating transcription factor (ATF)-1, a transcription factor of
the CREB/ATF family. Silencing of ATF-1 gene by RNA inter-
ference significantly reduced the induction of NOX1 by PGF2α or
PDGF, while overexpression of ATF-1 recovered the level of
NOX1 mRNA suppressed by oligomycin. Thus, ATF-1 was shown
to play a pivotal role in the up-regulation of NOX1 in VSMC.(50)
We next demonstrated that PGF2α enhanced the phosphorylation
of the epidermal growth factor (EGF) receptor, and a selective
inhibitor of EGF receptor kinase, tyrphostin AG1478, significantly
suppressed PGF2α-induced NOX1 expression in A7r5 cells.(51)
AG1478 also blunted the PGF2α-induced phosphorylation of
ERK1/2 and Akt. PI3 kinase inhibitors not only reduced PGF2α-
induced NOX1 expression, but also suppressed the phosphoryla-
tion of ATF-1. Accordingly, the transactivation of the EGF
receptor and the activation of ERK1/2, PI3 kinase, and ATF-1
were shown to constitute the signaling pathways involved in the
up-regulation of NOX1 (Fig. 3).(51) On the other hand, an oxidized
extracellular oxidation-reduction state (E(h)) increased the expres-
sion of NOX1.(52) When aortic segments and cultured VSMC were
exposed to E(h) between −150 mV (reduced) and 0 mV (oxidized)
by altering the concentration of cysteine and its disulfide, cystine,
a more oxidized E(h) increased the expression of NOX1 and
resulted in NOX1-dependent proliferation of VSMC. The induc-
tion of NOX1 was mediated by the EGF receptor, ERK1/2, and
ATF-1 as reported previously.(51)
Since the receptor for PGF2α is known to activate PKC, involve-
ment of PKC in the up-regulation of NOX1 expression was inves-
tigated in A7r5 cells.(53) Among isoform-selective inhibitors, an
inhibitor of PKCδ, rottlerin, significantly attenuated the PGF2α-
induced increase in NOX1 mRNA. Gene silencing of PKCδ by
Fig. 3. Signaling pathways and transcription factors involved in the expression of NOX1 and NOX4. Ovals indicate binding sites for transcription
factors on NOX genes. Transcription factors were expressed as boxes.doi: 10.3164/jcbn.11 06SR
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RNA interference significantly suppressed the PGF2α-induced
increase in NOX1 mRNA as well as phosphorylation of the EGF
receptor, ERK1/2, and ATF-1. Silencing of the PKCδ gene also
attenuated the PDGF-induced increase in NOX1 mRNA and trans-
activation of the EGF receptor. Thus, PKCδ was shown to mediate
the transactivation of the EGF receptor elicited not only by PGF2α,
but also by PDGF, and the subsequent activation of ERK1/2 and
ATF-1 leads to the up-regulation of NOX1 expression (Fig. 3).(53)
To further clarify the mechanisms underlying the transcriptional
regulation of NOX1 by vasoactive factors, we analyzed the 5'-end
of the rat NOX1 mRNA isolated from cultured VSMC and A7r5
cells.(54) NOX1 mRNA expressed in rat VSMC contained an exon
homologous to the exon 1c of the mouse NOX1 gene at the 5'-end.
However, neither the counterpart of mouse exon 1b, nor the
sequence encoding the additional N-terminal peptide was identified.
Reporter assays revealed that the binding site of myocyte enhancer
factor 2 (MEF2) at −139/−130 was essential for the up-regulation
of NOX1 by PGF2α. Stimulation of A7r5 cells with PGF2α
increased binding of MEF2 to this sequence. Among four subtypes
of MEF2, the expression level of MEF2B was extremely low, but
was elevated by stimulation with PGF2α or PDGF. RNA inter-
ference against MEF2B suppressed the induction of NOX1 by
PGF2α or PDGF. In addition, RNA interference against ATF-1
suppressed the induction of MEF2B by PGF2α or PDGF. Thus, the
induction of NOX1 in VSMC was mediated by MEF2B, of which
induction was dependent on the activation of ATF-1 (Fig. 3).(54)
We also identified an AP-1 binding site at −98/−92 essential for
NOX1 expression in rat VSMC. PGF2α and PDGF augmented the
binding of JunB to this sequence, and an inhibitor of MAPK/ERK
kinase suppressed the expression of JunB induced by PGF2α or
PDGF.(55) Thus, not only the ATF-1-MEF2B pathway but also the
ERK1/2-JunB pathway seems to regulate the inducible expression
of NOX1 in VSMC (Fig. 3).
Crosstalk between NOX1 and NF κB. Stimulation with a
TLR4 agonist LPS induced the expression of NOX1 in mouse
macrophage, and O2￿− derived from NOX1 was thought to take part
in foam cell formation.(31) The NOX1 mRNA species expressed in
the macrophage was the a-type. The induction was mediated by
NF-κB, and a NF-κB binding site was found at −91/−82 of the
mouse a-type NOX1 promoter.(31) Induction of NOX1 by LPS was
also reported in gastric mucosal cells.(34) Thus, NF-κB might be a
crucial transcription factor for the inducible expression of NOX1
in various cell types (Fig. 3). On the other hand, Kim et al.(32)
reported that NOX1-derived O2￿− is involved in IL-1β-induced
activation of NF-κB and transcriptional activation of IL-8 gene
in mast cells. IL-1β was shown to induce NOX1 expression via
leukotriene (LT) B4-BLT2 receptor signaling. Accordingly, there
seems to be a positive feedback loop in which NF-κB activation
by NOX1-derived O2￿− leads to induction of NOX1 and further
amplifies O2￿− production.
Physiological roles of NOX1/NADPH oxidase in cardio 
vascular system. The analyses of NOX1 gene-modified mice
have been mainly focused on cardiovascular biology. This is
because NOX1 is up-regulated by various vasoactive factors such
as Ang II and PGDF. We generated NOX1 gene-disrupted mice
and reported a pivotal role for NOX1-derived ROS in the pressor
response to Ang II.(56) NOX1 deficiency did not affect baseline
blood pressure. After Ang II infusion, a significant increase was
observed in mean blood pressure, accompanied by augmented
expression of NOX1 mRNA and production of O2￿− in the aorta of
wild-type mice. In contrast, the elevation in blood pressure and
production of O2￿− were significantly blunted in NOX1-deficient
mice. Ang II-mediated elevation of blood pressure was not
affected by administration of a NO synthase inhibitor L-NAME to
wild-type mice, but the reduced pressor response to Ang II in
NOX1-deficient mice was abolished by L-NAME. Gavazzi et al.(57)
also investigated the role of NOX1 in blood pressure regulation,
and reported similar results. ROS derived from NOX1/NADPH
oxidase were hence suggested to play a pivotal role in the pressor
response to Ang II.
In chronic hypertension model, on the other hand, Yogi et al.(58)
showed no relationship between NOX1 and blood pressure regula-
tion. When NOX1-deficient mice were crossed with transgenic
mice expressing human renin (TTRhRen), four genotypes were
generated: control, TTRhRen, NOX1-deficient, and TTRhRen/
NOX1-deficient mice. Unlike in the hypertension model induced
by short-term Ang II-infusion, NOX1 deficiency had no effect on
the development of hypertension in TTRhRen mice despite a
significant reduction in oxidative stress. The phosphorylation of
redox-sensitive signaling molecules and expression of proinflam-
matory mediators in the kidney were significantly attenuated
in  TTRhRen/NOX1-deficient mice. These alterations, however,
affected neither the blood pressure nor structural findings associated
with renal fibrosis. NOX1/NADPH oxidase may thus play a key
role in the modulation of specific redox signaling pathways, but
not in the development of hypertension when the endogenous
renin-angiotensin system is chronically elevated. These studies
indicated that NOX1-derived ROS may play different roles depen-
dent on the model of hypertension.
The implication of NOX1 in neointimal formation was shown
by Lee et al.(59) When neointimal formation was induced by wire-
injury in femoral artery of NOX1-deficient mice and smooth
muscle-specific NOX1-overexpressing mice (SM-NOX1-Tg),
neointimal formation was significantly reduced in NOX1-deficient
mice, but not in SM-NOX1-Tg. The proliferation and migration of
VSMC were reduced in NOX1-deficient mice, while they were
enhanced in SM-NOX1-Tg. In NOX1-deficient cells altered phos-
phorylation of cofilin and expression of mDia1 and PAK1, impor-
tant regulators of the actin cytoskeleton, were demonstrated. Over-
expression of S3A, a constitutively active cofilin mutant, partially
recovered reduced migration of NOX1-deficient cells. Taken
together, NOX1 appears to enhance neointimal formation by pro-
moting cell migration via regulation of cofilin activity.
A different line of study indicated the involvement of NOX1-
derived ROS in aortic dissection. Gavazzi et al.(60) showed that
Ang II-induced dissection of aorta was significantly suppressed
in NOX1-deficient mice. The underling mechanism was suggested
to be NOX1-dependent regulation of tissue inhibitor of metallo-
proteinase 1 (TIMP-1) expression, which could lead to tissue
damage through an altered protease/inhibitor balance. NOX1-
derived ROS may be an important factor not only in aortic dissec-
tion but also in aneurysm formation.(60)
Physiological roles of NOX1/NADPH oxidase in the nervous
system. We previously reported the involvement of NOX1 in
inflammatory pain.(61) While there was no difference in nocicep-
tive responses to heat or mechanical stimuli between wild type and
NOX1-deficient mice, thermal and mechanical hyperalgesia was
significantly attenuated in NOX1-deficient mice. To delineate the
molecular mechanisms underlying the reduced hyperalgesia ob-
served in NOX1-deficient mice, we isolated dorsal root ganglia
(DRG) neurons and examined the activity of TRPV1, a cation
channel implicated in the development of thermal hyperalgesia. In
DRG neurons derived from wild type mice, pretreatment with a
PKC activator TPA augmented the elevation of intracellular
calcium by capsaicin, an agonist of TRPV1. In contrast, this eleva-
tion was significantly attenuated in NOX1-deficient mice. Interest-
ingly, NOX1-deficiency or treatment with ROS-scavenging agents
perturbed TPA-induced translocation of PKCε. In cells transfected
with tagged PKCε, H2O2 induced translocation and a reduction in
free sulfhydryls of full-length PKCε, but not of the deletion
mutant lacking the C1A domain. These findings suggest that
NOX1-derived ROS oxidize the C1A domain of PKCε and
accelerate the translocation of PKCε to plasma membranes in
DRG neurons, thereby enhancing the TRPV1 activity and the
sensitivity to painful stimuli.(61)
In brain microglia, a novel function of NOX1 was docu- J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 15
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mented.(62) LPS, which elicits proinflammatory and neurotoxic
activation of microglia, stimulated NOX1-derived O2￿− production
and enhanced the expression of inducible NO synthase (iNOS). By
injecting LPS in the striatum, microglial production of cytotoxic
nitrite species and loss of presynaptic proteins in striatal neurons
were demonstrated in wild type mice, but not in NOX1-deficient
mice. Thus, microglial NOX1 may contribute to immune defenses
and the neural tissue damage that occurs in neurodegenerative and
inflammatory diseases.(62)
The involvement of NOX1 in the pathophysiology of cerebral
ischemia was documented, although underling molecular mecha-
nisms were not fully elucidated.(63) The expression of NOX1 was
detected in all cell types cultured from the brain with a relatively
similar expression level. In the middle cerebral artery occlusion
model, smaller brain infarcts were observed in NOX1-deficient
mice, accompanied by the preservation of blood-brain barrier and
reduced cerebral edema. These beneficial effects of NOX1-
deficiency were, however, blunted as the period of ischemia
extended (2 h and more). The apoptotic responses in the ischemic
core, the boundary, and the contralateral striatum were similar
between the two genotypes. Infusion of an antioxidant TEMPOL
or a NO synthase inhibitor L-NAME did not affect the ischemic
tissue damage between wild type and NOX1-deficient mice. These
results suggested that NOX1-derived ROS may be involved in
ischemia/reperfusion-associated tissue damage and blood-brain
barrier disruption in experimental stroke. ROS-mediated direct
cellular injury was, however, unlikely to explain the protective
effect achieved by genetic deletion of the enzyme.(63)
Physiological roles of NOX1/NADPH oxidase in the lung.
A crucial role of NOX1 was demonstrated in hyperoxia-induced
acute lung injury.(64) When exposed to a high concentration of
oxygen, wild type mice exhibited features of severe lung damage.
In contrast, hyperoxia-induced lung injury was significantly
attenuated in NOX1-deficient mice. Increased NOX1 expression
and NOX1-derived ROS production were observed in alveolar
epithelial type II cells and endothelial cells isolated from adult
mouse lung exposed to hyperoxia. Hyperoxia-induced cellular
apoptosis was markedly attenuated in NOX1-deficient mice.
Furthermore,  NOX1-deficiency decreased hyperoxia-induced
phosphorylation of Jun-N-terminal kinase (JNK) and ERK in
alveolar cells. These findings suggest an important role of NOX1
in hyperoxia-induced lung injury through regulation of apoptosis
in alveolar epithelial and endothelial cells via JNK- and ERK-
dependent pathways.(64)
Physiological roles of NOX1/NADPH oxidase in the colon.
Although NOX1 is abundantly expressed in the colon, there are
few reports concerning its function in the gastrointestinal tract.
Recently, Coant et al.(46) reported that the fate of proliferative pro-
genitor cells in the colon was controlled by the pathway dependent
on NOX1. In the colon of NOX1-deficient mice, a significant
increase in the number of differentiated goblet cells was observed.
The absence or presence of NOX1 in cultured colon cancer cells
affected the expression of goblet- or enterocyte-specific differ-
entiation factors, respectively. NOX1-deficiency perturbed cell
cycle entry of progenitor cells and influenced cell positioning in
the crypts. In accordance with these findings, PI3 kinase/Akt/Wnt/
β-catenin and Notch1 signaling was repressed in NOX1-deficient
mice. Concomitantly, reduced expression of MMP2/9 known to
take part in Notch1 activation was demonstrated. The activity of
PTEN, a dual-specificity phosphatase that antagonizes PI3 kinase/
Akt signaling, was enhanced in NOX1-deficient mice with altered
oxidation and phosphorylation status. This led to the inactivation
of the Wnt pathway effector β-catenin that promotes cell pro-
liferation. Thus, NOX1 was suggested to control the balance
between goblet and absorptive cell types in the colon by coordi-
nately modulating PI3 kinase/Akt/Wnt/β-catenin and Notch1 sig-
naling.(46)
NOX3
NOX3 gene was identified in the otoconia-deficient head tilt
mice. In these mice, an allelic series of mutations in the otoconia-
deficient head tilt (het) locus was found, causing null mutation or
point mutations in the NADPH binding site of NOX3.(65) Thus,
NOX3 appears to be essential for gravity perception.
The expression of NOX3 is almost restricted to the inner ear. In
situ hybridization demonstrated that NOX3 mRNA was expressed
in the vestibular and cochlear sensory epithelia and in the spiral
ganglions.(66) To date there is no report on the mechanism under-
lying the inner ear-specific expression of NOX3.
The activity of NOX3 has been documented to depend on
p22phox and NOX organizers (p47phox or NOXO1), activators
(p67phox or NOXA1), and Rac1 (Fig. 1).(35,66–68)
Molecular evolution study by Kawahara et al.(69) revealed that
NOX3 emerged relatively late in evolution, corresponding to the
permanent transition of vertebrates from water to land. Although
fish and amphibians have otoconia, they do not have NOX3 gene,
suggesting a unique function of NOX3 in land vertebrates.
Recently, the involvement of NOX3 in cisplatin-induced hearing
loss was reported. Knockdown of NOX3 using siRNA abrogated
cisplatin ototoxicity, as evidenced by protection of outer hair cells
from damage and reduced threshold shifts in auditory brainstem
responses in the rat. Transtympanic administration of NOX3
siRNA reduced the expression of TRPV1 and kidney injury
molecule-1 (KIM-1), biomarkers of cochlear damage. Concomi-
tantly, NOX3 siRNA reduced the expression of Bax, recovered the
decreased expression of Bcl2, and attenuated apoptosis induced by
cisplatin in the cochlea.(70) Thus, selective inhibitors of NOX3, of
which expression is almost restricted to the inner ear, would be
useful for preventing cisplatin ototoxicity.
Another line of study demonstrated a novel role of NOX3 in
insulin resistance.(71) In db/db mice, increased expression of
NOX3 and generation of ROS were demonstrated in the liver,
which was accompanied by increased accumulation of lipid
compared with wild type mice. Treatment of a human hepato-
cellular carcinoma cell line HepG2 with palmitate, the main
component of plasma free fatty acids, significantly elevated ROS
production, NOX3 expression, and gluconeogenesis. Hepatic
insulin resistance induced by palmitate was mediated by JNK and
p38 MAPK pathways, and rescued by RNA interference against
NOX3. A different line of investigation demonstrated that an anti-
NOX3 siRNA prevented the TNF-α-induced decrease in cellular
glycogen. In TNF-α-treated HepG2 cells, NOX3-dependent
activation of JNK, inhibition of IRS-1, and phosphorylation of
Akt and glycogen synthase kinase (GSK) were observed.(72) These
studies were, however, carried out in cultured cells and could not
verify whether NOX3 is a source of ROS in vivo. Further investi-
gations using NOX3 gene-modified mice may be required to
clarify the role of NOX3 in insulin resistance.
NOX4
Identification of NOX4. NOX4 was first identified as “renal
NOX” and later found in various tissues.(73–75) It was reported that
NOX4 requires only p22phox to exert its enzymatic activity
(Fig. 1). NOX4 was shown to generate H2O2, rather than O2￿−,
constitutively without other cytosolic components. Recently, it
was reported that the C-terminal half (dehydrogenase domain) of
NOX4/NOX2 determines the dependency on the cytosolic compo-
nents for the enzyme activation.(76,77) Another report demonstrated
that the activity of NOX4 is determined by mRNA levels.(78) Thus,
the expression level of NOX4 seems to imply its enzymatic
activity. Recently, polymerase (DNA-directed) delta-interacting
protein 2 (Poldip2) was reported to interact with p22phox and
enhance the activity of NOX4/NADPH oxidase.(79) Subcellular
localization of NOX4 was demonstrated in focal adhesions,doi: 10.3164/jcbn.11 06SR
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stress fibers, and nucleus of VSMC.(79) NOX4 was also detected
in perinuclear region of pulmonary arterial smooth muscle
cells (PASMC),(80) endoplasmic reticulum (ER) of exogenously
transfected cells,(76) and in mitochondria of mesangial cells and
cardiomyocytes.(81,82)
Constitutive and ubiquitous expression of NOX4. In con-
trast to NOX1, of which expression is induced by various
bioactive factors in specific cell types, NOX4 is constitutively ex-
pressed in various cell lineages. Ubiquitous expression of NOX4
suggests it as a housekeeping gene. Indeed, the promoter region of
the  NOX4 gene contains multiple GC bases, characteristics of
housekeeping genes. Zhang et al.(83) reported that E2F1 transcrip-
tion factor is involved in the expression of NOX4 in vascular
smooth muscle cells in rodents. We recently found that Sp3 tran-
scription factor is crucial for transcriptional activation of the human
NOX4 gene.(84) In the 5'-flanking and non-coding regions of the
human NOX4 gene, three GC-boxes containing putative Sp/Klf
binding sites were found, which were not conserved in rodent
genes. Reporter assays using SH-SY5Y and HEK293 cells
demonstrated that these GC-boxes were essential for the basal
expression of the NOX4 gene. Electrophoresis mobility shift
assays and chromatin immunoprecipitation assays demonstrated
that Sp1 and Sp3 could bind to GC-boxes at −239/−227 and +69/
+81 in these cells. By transfection of an anti-Sp3 short hairpin
RNA-expression plasmid, promoter activity of the NOX4 gene
was reduced in SH-SY5Y and HEK293 cells. Thus, Sp3, which is
expressed ubiquitously and involved in the expression of various
genes, seems to play a key role in the expression of NOX4 in
various cell lineages in humans (Fig. 3).(84)
Inducible expression of NOX4. On the other hand, inducible
expression of NOX4 was also reported. Hypoxia has been reported
to induce NOX4 expression in PASMC.(80,85) Transforming growth
factor (TGF)-β has also been known to induce the expression of
NOX4 in various cell types.(86–89) Cannabidiol, a nonpsychoactive
cannabinoid, was reported to induce the expression of NOX4 with
p22phox, and cellular apoptosis in human leukemia cells. This
effect was mediated by cannabinoid receptor 2 (CB2).(90) A major
oxysterol contained in oxidized low-density lipoprotein, 7-
ketocholesterol, was reported to induce the expression of NOX4 in
human aortic SMC. This induction was mediated by IRE-1 (an
ER-membrane kinase), JNK, and AP-1. Since NOX4 was shown
to induce ER stress and apoptosis, these findings suggest that
NOX4 is involved in oxysterol-induced SMC death and the patho-
genesis of atherosclerosis.(91) On the other hand, ursolic acid, an
active constituent of natural herbs, was reported to suppress the
expression of NOX4 in endothelial cells. These natural compounds
might therefore exert their beneficial effects by suppressing
NOX4 expression that leads to the increase in bioactive NO.(92)
Induction of NOX4 expression by hypoxia. NADPH oxi-
dases have been suggested to serve as oxygen sensors in the
lung. Chronic hypoxia induces vascular remodeling with medial
hypertrophy and leads to the development of pulmonary hyper-
tension. Mittal et al.(80) reported that NOX4 is expressed in the
media of small pulmonary arteries and the expression level was
increased in mice exposed to chronic hypoxia. Induction of NOX4
was also observed in isolated PASMC exposed to hypoxia. Also in
patients with idiopathic pulmonary arterial hypertension, the level
of NOX4 expression was up-regulated in the lung. Treatment of
PASMC with an anti-NOX4 siRNA significantly reduced the
proliferation of PASMC. Diebold et al.(85) found a putative hypoxia
responsive element in the human NOX4 promoter and demonstrated
that this sequence is indispensable for the binding of hypoxia-
inducible factor-1α (HIF-1α). In fact, RNA interference against
HIF-1α suppressed hypoxia-induced expression of NOX4. The
involvement of NF-κB in the hypoxia-induced expression of NOX4
was further reported in PASMC, in that hypoxia increased binding
of NF-κB p65 to the putative NF-κB binding site adjacent to the
putative hypoxia responsive element. Interestingly, rosiglitazone,
a PPARγ agonist, suppressed the binding of NF-κB and the pro-
moter activity of NOX4.(93) Thus, NOX4 appears to be a target
gene of HIF-1α and NF-κB under hypoxic condition (Fig. 3).
NOX4 induced by hypoxia might be involved in the pathogenesis
of various cardiovascular diseases through vascular remodeling.
Induction of NOX4 expression by TGF β. The expression
of NOX4 was induced by TGF-β in cardiac fibroblasts, smooth
muscle cells of the pulmonary artery and airway, and in hepato-
cytes.(86–89) TGF-β up-regulated the expression of NOX4 in Hep3B
cells but not in HepG2 cells, both of which are human hepato-
cellular carcinoma cell lines.(89) Treatment with PD98059 recovered
the reactivity of HepG2 cells to TGF-β, suggesting that the MEK/
ERK pathway is involved in the regulation of NOX4 expression.(94)
A role for NOX4 in tissue repair and fibrogenesis has been
documented. TGF-β1 induced NOX4 expression in lung mesen-
chymal cells via Smad3, a receptor-regulated protein that modu-
lates gene transcription. NOX4-derived H2O2 was required for
TGF-β1-induced myofibroblast differentiation, extracellular ma-
trix production and contractility. NOX4 was up-regulated in mice
subjected to bleomycin- or hapten-induced pulmonary injury, as
well as in patients with idiopathic pulmonary fibrosis (IPF). RNA
interference against NOX4 abrogated fibrogenesis in two murine
models of lung injury. Thus, selective inhibitors of NOX4 may be
useful for the treatment of fibrotic disorders, if appropriate drug
delivery systems were established.(95) In the kidney, NOX4 seems
to be also involved in the pathogenesis of fibrotic diseases.
Increased expression of NOX4 in a rat model of type 1 diabetes
induced by streptozotocin was reported, and the involvement of
NOX4 in glomerular hypertrophy and fibronectin expression,
features of diabetic nephropathy, was suggested.(81)
In vivo analyses using NOX4 gene modified mice and
gene transfer. While NOX4 is ubiquitously expressed in
various tissues, the roles for NOX4-derived ROS are somewhat
controversial. NOX4 acts as a regulator of proliferation, hyper-
trophy, and cell survival,(80,87,88,96,97) whereas it acts as a regulator of
apoptosis and differentiation in some cell types.(82,89–91,94,98) The
reason for these discrepancies has not been clarified yet.
On the other hand, in vivo functions of NOX4 were mainly
investigated in cardiac tissue. Ago et al.(82) generated two types
of NOX4-transgenic mice. One was with cardiac-specific over-
expression of NOX4 (Tg-NOX4), and the other was with
catalytically-inactive NOX4 (Tg-NOX4-P437H). The catalytically-
inactive NOX4 cannot form a heterodimer with p22phox and
thereby inhibits production of O2￿− by endogenous NOX4. Expres-
sion of NOX4 in cardiac tissues was up-regulated by aging as well
as by hypertrophic stimulation such as pressure overload. During
young age, the cardiac phenotype of Tg-NOX4 or Tg-NOX4-
P437H was not much different from that of wild type mice.
However, at 13 to 14 months old, Tg-NOX4 mice showed severe
cardiac dysfunction with increased ROS production, apoptosis,
and fibrosis in cardiac tissues. In agreement with the finding in the
kidney,(99) NOX4 was identified in mitochondria, and NOX4-
derived ROS was shown to elicit mitochondrial dysfunction by
oxidation of mitochondrial proteins involved in the TCA cycle and
electron transport chain.
The same group generated cardiac-specific NOX4 deficient
mice (c-NOX4−/−) and elucidated the function of NOX4 in cardiac
tissue.(100) When pressure overload was induced by transverse
aortic constriction (TAC), a significant increase in NOX4 expres-
sion and ROS production in mitochondria was observed in wild
type mice but not in c-NOX4−/−. Cardiac hypertrophy, interstitial
fibrosis, apoptosis, and cardiac dysfunction induced by TAC were
significantly attenuated in c-NOX4−/−. Furthermore, TAC-induced
mitochondrial swelling, cytochrome c release, and decreased mito-
chondrial DNA and aconitase activity were significantly attenuated
in c-NOX4−/−. These studies clearly indicated that NOX4 in cardiac
myocytes is a major source of mitochondrial oxidative stress, and
NOX4-derived ROS amplify mitochondrial and cardiac dysfunc- J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 17
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tion by oxidation of mitochondrial proteins.
As opposed to these findings, a protective role for NOX4 in
pressure overload-induced cardiac remodeling was demon-
strated.(101) In this study, NOX4-null mice (systemic NOX4 defi-
ciency) and cardiomyocyte-targeted NOX4 transgenic mice were
utilized. No difference in basal cardiac functions was observed
between the two genotypes. When suprarenal aortic constriction
was performed to generate chronic pressure overload, expression
of NOX4 was markedly increased in cardiac myocytes, along with
contractile impairment and ventricular dilatation in wild type
mice. Interestingly, NOX4-null mice developed greater cardiac
dilatation, contractile impairment, and cardiac hypertrophy com-
pared with wild type mice. In accordance with these findings,
cardiomyocyte-targeted  NOX4-transgenic mice were protected
against chronic pressure overload-induced stress. Taken together,
these results obtained through both loss-of-function and gain-of-
function approaches indicate that an increase in myocardial NOX4
expression is protective against chronic pressure overload-induced
cardiac dysfunction. As a major mechanism underlying the
beneficial effects of NOX4, preservation of capillary density in
myocardium, which was decreased in wild type mice and in
NOX4-null mice after chronic pressure overload, was suggested in
NOX4-transgenic mice. Indeed, decreased levels of HIF-1α and
vascular endothelial growth factor (VEGF) in NOX4-null mice
were recovered in NOX4-transgenic mice. NOX4-derived ROS
thus appear to regulate paracrine angiogenic activity by enhance-
ment of HIF-1α and VEGF expression to protect the heart from
chronic pressure overload-associated pathologies.
Hence the effects of NOX4-derived ROS in the heart have
been variable in the hands of different workers. It should be noted,
however, that NOX4 gene-modified mice and experimental models
of pressure overload applied in their studies were dissimilar. The
functional roles for NOX4 in cardiac tissues still remain contro-
versial and further investigations seem to be required.
In the paraventricular nucleus (PVN) of the hypothalamus, a
key regulator of sympathetic nerve activity, NOX4 was reported to
be an important mediator in myocardial infarction (MI)-induced
cardiac dysfunction.(102) After induction of MI by coronary arterial
ligation, the expression of NOX4 was up-regulated in PVN with
increased ROS production. To clarify the role of NOX4 in PVN,
adenoviral gene transfer of siRNA targeted against NOX4
(AdsiNOX4) to PVN was performed. PVN-targeted AdsiNOX4
suppressed the MI-induced ROS production in PVN, and im-
proved MI-induced cardiac dysfunction by attenuating chronic
sympathoexcitation, recovering left ventricle β-adrenergic receptor
responsiveness, and reducing periinfarct apoptosis. Targeted
inhibition of NOX4 in PVN might thus provide a novel treatment
strategy for MI-induced heart failure.
NOX5
NOX5 was identified as a Ca2+-dependent NADPH oxidase.(103)
It has four EF-hands, the Ca2+-binding domains, at the N-terminus
(Fig. 1). According to the evolutional analyses, Ca2+-regulated,
EF-hand-containing NOXes appeared very early during the evolu-
tion of eukaryotes.(69)
Unlike other NOX proteins, NOX5 does not require other
components for its activation (Fig. 1). Therefore, its activation is
dependent on Ca2+ levels.(104) Kawahara et al.(105) reported that
phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P2] plays a
key role in the translocation of NOX5 to the plasma membrane.
The polybasic region between the fourth EF-hand and the first
transmembrane region was shown to bind PtdIns(4,5)P2 and be
essential for membrane localization of NOX5. Jamali et al.,(106)
on the other hand, reported that H2O2 induced production of O2￿−
in K562 cells expressing NOX5. This activation was mediated
by Ca2+-dependent translocation of c-Abl non-receptor tyrosine
kinase to the membrane, where the association of NOX5 with c-Abl
was suggested.
Expression of NOX5 was demonstrated in the testis, spleen,
lymph nodes, and in VSMC.(103) Since NOX5 gene is absent in
rodents, analyses using gene-disrupted mice are not feasible.
Involvement of NOX5 in PDGF-induced proliferation of VSMC(107)
and in the regulation of growth and apoptosis of prostate cancer
cells(108) has been suggested. Expression of NOX5 was also
demonstrated in hairy cells (mature malignant B cells), but not in
circulating normal B cells.(109) NOX5-derived oxidants were
shown to inhibit SHP-1 phosphatase, suggesting that NOX5 is
involved in the constitutive phosphorylation signals in hairy
cells.(109) In Barrett's esophageal adenocarcinoma, overexpression
of NOX5 and the involvement in carcinogenesis were suggested.
Platelet-activating factor (PAF) was shown to induce NOX5 ex-
pression in esophageal adenocarcinoma cells, and this induction
was mediated by the binding of STAT5 to an element in the NOX5
promoter.(110)
DUOX1 and DUOX2
DUOX1 and DUOX2 were initially identified as homologs of
NOX2 in the thyroid gland.(111,112) The structure of DUOX is
composed of the NOX-like region at the C-terminal half, two
EF-hands, a membrane-spanning region, and a peroxidase-like
domain at the N-terminus (Fig. 1). Therefore they were designated
as dual-oxidase, DUOX. H2O2 derived from DUOX2 is essential
for the synthesis of thyroid hormones by thyroid peroxidase.
Mutations in the DUOX2 gene were reported in congenital hypo-
thyroidism.(113,114)
DUOX does not require other components of NADPH oxidase
for its activity. However, DUOX maturation factors named
DUOXA1 and DUOXA2 were identified as transmembrane pro-
teins essential for ER-to-Golgi transition, maturation, and targeting
DUOX1 and DUOX2, respectively, to the plasma membrane as
functional complexes.(115,116) DUOXA1 was originally identified as
numb-interacting protein 1 (NIP1). DUOXA1 and DUOXA2 genes
were arranged in a head-to-head orientation and co-expressed
with DUOX1 and DUOX2 genes, respectively. A mutation in the
DUOXA2 gene was also reported in congenital hypothy-
roidism.(117) Rigutto et al.(118) reported differential activation of
DUOX1 and DUOX2 by protein kinases. DUOX1 but not
DUOX2 activity was stimulated by forskolin via protein kinase A-
mediated phosphorylation of DUOX1 on serine 955, while TPA
induced DUOX2 phosphorylation via PKC activation.
Both DUOX1 and DUOX2 were highly expressed in the thyroid
gland. DUOX1 is also expressed in the airway epithelia, placenta,
prostate, testis, pancreas, and in the heart.(119,120) DUOX2 is ex-
pressed in epithelial cells in salivary excretory ducts and rectal
glands.(120,121) As lactoperoxidase (LPO), an enzyme with anti-
microbial properties, was detected in airway secretions and saliva,
DUOX enzymes may play essential roles in host defense by
supplying H2O2 to LPO.(120) The expression of DUOX1 in the
airway epithelia was increased by the treatment with Th2 cyto-
kines IL-4 and IL-13, whereas the expression of DUOX2 was
highly induced by the treatment with the Th1 cytokine IFN-γ.
Differential regulation of DUOX1 and DUOX2 by Th1 and Th2
cytokines might be important for host defense and inflammatory
responses. The expression of DUOX2 was also up-regulated by
polyinosine-polycytidylic acid and by rhinovirus infection.(122) In
lung cancer cells, the expression of DUOX1 and DUOX2 is often
suppressed by hypermethylation of the CpG-rich promoter regions
in the genes.(123)
Inhibitors of NOX/NADPH Oxidases
Diphenyleneiodonium (DPI) is the compound that has been
most frequently used as an inhibitor of NOX/NADPH oxidases
(Fig. 4). DPI is, however, a nonselective inhibitor of flavin-doi: 10.3164/jcbn.11 06SR
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containing enzymes including nitric oxide synthases, cytochrome
P450s, and NADH-ubiquinone oxidoreductase (complex I of the
mitochondrial respiratory chain). In fact, as mentioned before,
DPI inhibits an inducible expression of NOX1 in VSMC probably
via inhibition of NADH-ubiquinone oxidoreductase.(50) Thus,
due to its selectivity and cytotoxicity, the usefulness of DPI may
be limited to in vitro experiments.
Apocynin (acetovanillone, 4-hydroxy-3-methoxyacetophenone)
has been also used as an inhibitor of NOX/NADPH oxidases
(Fig. 4). Apocynin was thought to inhibit the binding of p47phox
to NOX2. Recently, however, apocynin was reported to act as an
antioxidant rather than an inhibitor of NADPH oxidase. In leuko-
cytes, apocynin is a prodrug that is activated by myeloperoxidase,
a process that results in the formation of apocynin dimers. Cells
lacking myeloperoxidase failed to generate these dimers and,
therefore, are unable to activate apocynin. Thus, apocynin seems
to inhibit NADPH oxidase in leukocytes, while it could act as an
antioxidant in other cell lineages.(124)
A specific peptide inhibitor of NADPH oxidase, gp91ds-tat,
was developed by Pagano and his colleagues.(125) It is a chimeric
peptide consisting of 9 amino acids derived from a HIV-coat
protein (tat) and a 9-amino acid sequence of NOX2 known to
interact with p47phox (docking sequence) (Fig. 4). The 9 amino
acids derived from HIV tat protein give the peptide cell permea-
bility. Thus, gp91ds-tat interferes with the assembly and activation
of NOX2-containing NADPH oxidase. As gp91ds-tat binds to
p47phox, it could inhibit the activity of NOX1-containing
NADPH oxidase. Oral administration of gp91ds-tat is basically
unsuitable due to its low bioavailability as a peptide. Besides,
potential immunogenicity of the chimeric peptide containing tat
protein may limit the use of this inhibitor in animal studies.
Recently, high-throughput screenings for selective NOX4
inhibitors were performed. Cells transfected with NOX4 or the
membrane fractions of the transfectants were utilized for the
screening. Vichem Chemie Research (Hungary) identified three
compounds that inhibit NOX4 activity for further drug develop-
ment. One is a phenantridinone derivative, another is an iso-
flavone derivative, and the other is an oxalylamide derivative.(126)
Genkyotex (Switzerland) developed a selective NOX4/1 inhibitor,
GKT136901, which has low affinity to other NOX enzymes
(Fig. 4). High plasma concentration of the inhibitor could be
achieved by oral administration in rats.(127,128) Thus, GKT136901 is
currently expected for further clinical trials for the treatment of
NOX4/1-related disorders such as pulmonary fibrosis, cancers,
and cardiovascular and metabolic diseases.
Conclusions
We summarized isoform-specific activation mechanisms, tran-
scriptional regulation, and physiological roles of NOX/DUOX-
containing NADPH oxidases. Studies using gene-modified animals
may further clarify the entire picture of their unidentified roles. In
the meantime, development of isoform-selective NOX inhibitors
is expected for the treatment of a wide range of acute and chronic
diseases.
Abbreviations
AB apoptotic bodies
ad-TRAIL adeno-tumor necrosis factor-related apoptosis-
inducing ligand
AIR autoinhibitory region
ALS amyotrophic lateral sclerosis
Ang II angiotensin II
ATF activating transcription factor
BDL bile duct ligation
BID binding increased during differentiation
BM bone marrow
BMC bone marrow-mononuclear cells
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